

Dr. Channing Paller is associate professor of Oncology and Urology at Johns Hopkins University and director of prostate cancer clinical research at the Sidney Kimmel Comprehensive Cancer Center. She is also associate director for Oncology of the Johns Hopkins Clinical Research Network and is focused on the care of patients with genitourinary cancer. She holds a Department of Defense prostate cancer clinical trial consortium grant as one of the nationally funded sites. Dr. Paller is the co-lead investigator of the prostatecancerpromise.org "PROMISE" study screening 5,000 men for genetic mutations and following 500 of them to help match them to targeted therapies.

She earned her M.D. at Harvard Medical School and completed her medical residency at the Johns Hopkins Hospital, where she was a member of the Osler Housestaff Program, and completed her fellowship in Medical Oncology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. As an expert in clinical trial design, Dr. Paller is focused on biomarker research and clinical trials of developmental therapeutics in prostate cancer. She was the former president of GUMDROP (Genitourinary Multidisciplinary D.C. Regional Oncology Project) and the current secretary, where she works with other oncologists, radiation oncologists, and urologists to provide personalized and targeted treatments for prostate cancer patients. Her passion is helping to make a difference in a personalized care for the lives of cancer patients. As an advisor for the innovation in cancer informatics fund, she works to lower barriers to innovation and impact patient care and treatment options.

She has a fascination with cyber and looking at how the data, analysis and other practices of oncology may cross over to cybersecurity.